Our Company
AIKO Biotechnology, Inc. ("AIKO") is an early stage drug discovery company founded to characterize and validate therapeutic candidates for the management of pain, addiction and adverse side effects resulting from prescription opioid pain reliever use.
AIKO's lead drug candidates will significantly increase the safety and efficacy of opioids that are used by millions of pain sufferers, with the ultimate goal to provide safe analgesics with minimal side effects while eliminating the addictive and abuse potential of the most powerful pain relievers.
|
Our Compounds
AIKO-150 is the only known candidate drug suitable for co-formulation with an opioid analgesic that will confer both abuse resistance and limited side effects, particularly constipation.
AIKO-160 represents an ideal candidate for combination products with opioid analgesics, or as stand-alone therapy for peripheral opioid side effects, such as constipation and post operative ileus.
AIKO compounds are also well suited as stand-alone therapy for management of opioid overdose and addiction to narcotics, alcohol and nicotine.
|
Our News
AIKO Biotechnology announces that it has filed its first Investigational New Drug (IND) Application with the FDA to test the safety and efficacy of its lead compound, AIKO-150 in human trials, for the reduction of side effects resulting from the use of opioids...
More...
AIKO Biotechnology finalizes a $400,000 Development Award from the Maine Technology Institute to conduct human trials of its lead compound, AIKO-150...
More...
|
